Literature DB >> 18824673

Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?

D Chabas1, T Castillo-Trivino, E M Mowry, J B Strober, O A Glenn, E Waubant.   

Abstract

BACKGROUND: Multiple sclerosis (MS) onset before puberty may have a distinct clinical presentation. Pediatric patients with MS may less often meet MRI diagnostic criteria for adults. Whether initial MRI presentation is distinct in prepubertal patients is unknown.
METHODS: We queried the UCSF MS database for pediatric patients with MS (onset <or=18 years) who underwent brain MRI within 3 months of initial symptoms. The overall number of lesions and the number of well-defined and ovoid, large, confluent, and gadolinium-enhancing lesions were compared between patients with earlier-onset (EOPMS) (<11 years) and later-onset (LOPMS) (>or=11 years) pediatric MS. The next available brain MRI scan was used to evaluate lesion resolution.
RESULTS: Thirteen children with EOPMS (median age 8.90 years, range [3.58-10.98], 38% girls) and 18 with LOPMS (median age 14.47 years, range [11.78-18.00], 61% girls) were identified. While the overall number of T2-bright lesions was similar in the two groups, patients with EOPMS had fewer well-defined ovoid T2-bright lesions (median = 7, range [0-29] vs 21.5, [4-100]; p = 0.004) and more often had confluent lesions (31% of patients vs 0%; p = 0.02) on their first MRI compared with patients with LOPMS. Ninety-two percent of patients with EOPMS had a reduction in the number of T2-bright lesions on the second scan compared to 29% of patients with LOPMS (p = 0.002).
CONCLUSIONS: The distinct prepubertal multiple sclerosis (MS) MRI phenotype suggests that underlying biologic processes may differ in earlier-onset pediatric MS compared to later-onset pediatric MS. These findings may delay diagnosis in that age range. MRI criteria for MS diagnosis may need to be revised before puberty.

Entities:  

Mesh:

Year:  2008        PMID: 18824673     DOI: 10.1212/01.wnl.0000326896.66714.ae

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

Review 1.  Imaging in Pediatric Demyelinating and Inflammatory Diseases of the Brain- Part 1.

Authors:  Sniya Valsa Sudhakar; Karthik Muthusamy; Sunithi Mani; Sridhar Gibikote; Manohar Shroff
Journal:  Indian J Pediatr       Date:  2015-12-04       Impact factor: 1.967

2.  A longitudinal assessment of early pubertal timing as a predictor of psychosocial changes in adolescent girls with and without spina bifida.

Authors:  Rachel M Wasserman; Grayson N Holmbeck; Jaclyn M Lennon; Christina M Amaro
Journal:  J Pediatr Psychol       Date:  2012-01-23

3.  Sorting through the pediatric MS spectrum with brain MRI.

Authors:  Dorothée Chabas; Daniel Pelletier
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

Review 4.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

5.  [Inflammatory diseases of the central nervous system].

Authors:  Armin Bachhuber
Journal:  Radiologe       Date:  2021-06-08       Impact factor: 0.635

6.  Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis.

Authors:  Gregory Aaen; Michael Waltz; Wendy Vargas; Naila Makhani; Jayne Ness; Yolanda Harris; T Charles Casper; Leslie Benson; Meghan Candee; Tanuja Chitnis; Mark Gorman; Jennifer Graves; Benjamin Greenberg; Timothy Lotze; Soe Mar; Jan-Mendelt Tillema; Mary Rensel; Moses Rodriguez; John Rose; Jennifer Rubin; Teri Schreiner; Amy Waldman; Bianca Weinstock-Guttman; Anita Belman; Emmanuelle Waubant; Lauren Krupp
Journal:  J Child Neurol       Date:  2018-12-17       Impact factor: 1.987

7.  Therapeutic strategies in childhood multiple sclerosis.

Authors:  Angelo Ghezzi
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 8.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

9.  No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab.

Authors:  Monica Margoni; Francesca Rinaldi; Alice Riccardi; Silvia Franciotta; Paola Perini; Paolo Gallo
Journal:  J Neurol       Date:  2019-09-27       Impact factor: 4.849

10.  No evidence for impairment of venous hemodynamics in children or young adults with pediatric-onset multiple sclerosis.

Authors:  S Laughlin; C K Macgowan; J Traubici; K Chan; S Khan; D L Arnold; R A Marrie; B Banwell
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-18       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.